UBS Group’s Entasis Therapeutics Holdings Inc. ETTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-12,179
| Closed | -$27K | – | 11819 |
|
|
2022
Q2 | $27K | Buy |
12,179
+4,604
| +61% | +$9.19K | ﹤0.01% | 6541 |
|
|
2022
Q1 | $14K | Buy |
+7,575
| New | +$13.8K | ﹤0.01% | 8015 |
|
|
2021
Q4 | – | Sell |
-5,310
| Closed | -$18K | – | 11202 |
|
|
2021
Q3 | $18K | Buy |
5,310
+5,207
| +5,055% | +$14.1K | ﹤0.01% | 7313 |
|
|
2021
Q2 | $0 | Buy |
+103
| New | +$233 | ﹤0.01% | 10178 |
|
|
2021
Q1 | – | Sell |
-364
| Closed | -$1K | – | 9757 |
|
|
2020
Q4 | $1K | Sell |
364
-1,701
| -82% | -$3.35K | ﹤0.01% | 8301 |
|
|
2020
Q3 | $4K | Buy |
2,065
+461
| +29% | +$1.31K | ﹤0.01% | 7475 |
|
|
2020
Q2 | $5K | Buy |
1,604
+1,337
| +501% | +$3.65K | ﹤0.01% | 7407 |
|
|
2020
Q1 | $1K | Sell |
267
-2,716
| -91% | -$12.2K | ﹤0.01% | 7860 |
|
|
2019
Q4 | $15K | Buy |
2,983
+946
| +46% | +$5.12K | ﹤0.01% | 7073 |
|
|
2019
Q3 | $12K | Buy |
2,037
+1,537
| +307% | +$10.3K | ﹤0.01% | 7076 |
|
|
2019
Q2 | $3K | Sell |
500
-2,817
| -85% | -$18.1K | ﹤0.01% | 7563 |
|
|
2019
Q1 | $22K | Sell |
3,317
-2,534
| -43% | -$15.2K | ﹤0.01% | 6249 |
|
|
2018
Q4 | $24K | Buy |
5,851
+4,312
| +280% | +$28.4K | ﹤0.01% | 6653 |
|
|
2018
Q3 | $17K | Buy |
+1,539
| New | +$16.2K | ﹤0.01% | 6900 |
|
UBS Group's ETTX Position: Q3 2022 in Review
UBS Group sold out of Entasis Therapeutics Holdings Inc. (ETTX) in Q3 2022, closing a stake of 12,179 shares — an estimated $27K sold.
UBS Group first reported a position in ETTX in Q3 2018 and held it in 14 quarters. The position peaked at $27K in Q2 2022. 0 funds tracked by Wall St. Rank hold ETTX as of Q3 2022.
- UBS Group reported no remaining Entasis Therapeutics Holdings Inc. position as of Q3 2022 after selling out during the quarter.
- UBS Group sold 12,179 Entasis Therapeutics Holdings Inc. shares in Q3 2022, an estimated $27K.
- UBS Group first reported a position in Entasis Therapeutics Holdings Inc. in Q3 2018 and held it in 14 quarters.
- UBS Group's Entasis Therapeutics Holdings Inc. position peaked at $27K in Q2 2022.
- 0 funds tracked by Wall St. Rank held Entasis Therapeutics Holdings Inc. as of Q3 2022.
Based on UBS Group's 13F filing for Q3 2022, filed 10 Nov 2022.